Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06235190
Other study ID # FSK-CIP-2
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 27, 2024
Est. completion date November 2025

Study information

Verified date May 2024
Source Fasikl Inc.
Contact Head of Clinical Affairs
Phone 1-507-403-7680
Email felixsupport@fasikl.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical study is to compare Felix NeuroAI Wristband and sham device in patients with essential tremor. The main question it aims to answer is: • Is Felix a safe and efficacious treatment for patients with essential tremor? Participants will be treated with either Felix or Sham for a period of up to 90 days. After that, they will be eligible to participate in a long-term, open-label study and be treated with Felix.


Description:

The TRANQUIL study is a prospective, randomized, sham-controlled, double-blinded, multi-center, multi-region trial. The objective of this clinical investigation is to evaluate the safety and effectiveness of the Felix NeuroAI Wristband to aid in the relief of upper limb tremor in adults with essential tremor (ET).


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date November 2025
Est. primary completion date November 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - At least 18 years of age. - Willing to provide written, informed consent to participate in the study. - A clinical diagnosis of ET by a movement disorder specialist. - For the dominant hand, a tremor severity score of 2 or higher as measured by one of the TETRAS Performance Subscale (PS) tasks (items 4, 6, 7, and 8) and a total score of 7 or higher across these items. If applicable, this must be met while the patient is on ET treatment. - Stable dosage of anti-tremor medications, if applicable, for 30 days prior to study entry. - Stable dosage of antidepressant medications, if applicable, for 90 days prior to study entry. - Familiar with operating a touch-screen smartphone and connecting to Wi-Fi internet at home. - If necessary, have a dedicated caregiver to help with study required activities, such as putting on the study device, etc. - Willing to comply with study protocol requirements including: 1. Remaining on a stable dosage of anti-tremor and antidepressant medications, if applicable, during the course of the study. 2. Do not start any new anti-tremor treatment during the course of the study (except the assigned treatment in the study). 3. Remaining on stable caffeine consumption, if applicable, during the course of the study. 4. No alcohol or marijuana consumption the day before a study visit. 5. Do not share study/device-related information on the internet or with other study patients. Exclusion Criteria: - Prior limb amputation or any known symptomatic peripheral neuropathy condition of the involved upper extremity. - Prior surgical intervention for ET such as deep brain stimulation or thalamotomy. - Moderate to severe alcohol use disorder (AUD) as per Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) (the presence of at least 4 symptoms or more). - Any current drug abuse. - Use of recreational drugs other than marijuana. - Current unstable epileptic conditions with a seizure within 6 months of study entry. - Other possible causes of tremor such as drug-induced tremor, enhanced physiological tremor, dystonia, and Parkinson's disease. - Pregnant or nursing subjects and those who plan pregnancy during the course of the study. - Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at the stimulation site. - Known allergy to adhesive bandages. - The presence of any cognitive or other impairment that in the judgement of the investigator will impede the assessment of study outcomes. - Botulinum Toxin injection for hand tremor within 4 months prior to study enrollment. - History of use of other transcutaneous afferent patterned stimulation (TAPS) devices such as Cala Trio. - Subject is currently participating or has participated in another interventional clinical trial in the last 30 days which may confound the results of this study, unless approved by the Sponsor. - Subject is unable to communicate with the investigator and study staff. - Any health condition that in the investigator's opinion should preclude participation in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Felix NeuroAI Wristband
The Felix NeuroAI Wristband (Felix) is a wrist-worn, noninvasive, transcutaneous neurostimulation system. Using a proprietary artificial intelligence (AI) algorithm, stimulation will be automatically adapted to patient's needs with the goal to provide full day relief of upper limb tremor.
Sham Device
The sham device has the same exterior appearance and components as the Felix device and is used the same way (without delivering the treatment).

Locations

Country Name City State
China Xuanwu Hospital Capital Medical University Beijing
China Sir Run Run Shaw Hospital Hangzhou
China Tianjin Medical University General Hospital Tianjin
United States Parkinson's Disease and Movement Disorders Center of Boca Raton Boca Raton Florida
United States Parkinson's Research Centers of America - Long Island Commack New York
United States The University Of Kansas Medical Center Kansas City Kansas
United States Columbia University Irving Medical Center New York New York
United States Parkinson's Research Centers of America - Palo Alto Palo Alto California

Sponsors (1)

Lead Sponsor Collaborator
Fasikl Inc.

Countries where clinical trial is conducted

United States,  China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Tremor Research Group Essential Tremor Rating Assessment Scale (TETRAS) modified Activities of Daily Living (mADL) score from baseline pre-stimulation to Day 90 TETRAS mADL score is a composite sum of items 2 to 11 of the TETRAS ADL subscale and items 6 (bilateral) and 7 (dominant hand) of the TETRAS performance subscale (PS). Each item is scored from 0 to 4, indicating increasing severity of tremor. TETRAS mADL score is calculated as the sum of all 12 items and ranges from 0 to 52. 90 days
Secondary Change in Tremor Research Group Essential Tremor Rating Assessment Scale (TETRAS) modified Activities of Daily Living (mADL) score from baseline pre-stimulation to 14 days, 30 days, 60 days, 180 days, and 1 year TETRAS mADL score is a composite sum of items 2 to 11 of the TETRAS ADL subscale and items 6 (bilateral) and 7 (dominant hand) of the TETRAS performance subscale (PS). Each item is scored from 0 to 4, indicating increasing severity of tremor. TETRAS mADL score is calculated as the sum of all 12 items and ranges from 0 to 52. 14 days, 30 days, and 60 days, 180 days, and 1 year
Secondary Responder Rate Responder rate is defined as the proportion of patients responding to the treatment, as defined by change in TETRAS mADL score at or above a pre-specified margin. 14 days, 30 days, 60 days, 90 days, 180 days, and 1 year.
Secondary Tremor Research Group Essential Tremor Rating Assessment Scale (TETRAS) performance subscale (PS) Items 1, 4, and 8 Each TETRAS PS item is scored by physician from 0 to 4, indicating increasing severity of tremor. Baseline, 30 days, 90 days, and 1 year
Secondary Tremor Research Group Essential Tremor Rating Assessment Scale (TETRAS) performance subscale (PS) Items 6 and 7 Each TETRAS PS item is scored by physician from 0 to 4, indicating increasing severity of tremor. Baseline,14 days, 30 days, 60 days, 90 days, 180 days, and 1 year.
Secondary Tremor Research Group Essential Tremor Rating Assessment Scale (TETRAS) performance subscale (PS) Dominant Hand Score The sum of TETRAS PS items 4, 6, 7, and 8 for the dominant hand. Each item is scored by physician from 0 to 4, indicating increasing severity of tremor. Baseline, 30 days, 90 days, and 1 year
Secondary Clinical Global Impression of Severity (CGI-S) Physician rating on a 7-point scale, from 1 (normal) to 7 (amongst the most extreme tremor) Baseline, 30 days, 90 days, and 1 year
Secondary Patient Global Impression of Severity (PGI-S) Patient rating on a 7-point scale, from 1 (normal) to 7 (amongst the most extreme tremor) Baseline, 14 days, 30 days, 60 days, 90 days, 180 days, and 1 year.
Secondary Clinical Global Impression of Improvement (CGI-I) Physician rating of tremor improvement on a 7-point scale, from 1 (very much improved) to 7 (very much worse) Baseline, 30 days, 90 days, and 1 year
Secondary Patient Global Impression of Improvement (PGI-I) Patient rating of tremor improvement on a 7-point scale, from 1 (very much improved) to 7 (very much worse) Baseline, 14 days, 30 days, 60 days, 90 days, 180 days, and 1 year.
Secondary Quality of Life in Essential Tremor Questionnaire (QUEST) QUEST is a 30-item scale developed specifically for patients with essential tremor to measure items impacting perceived quality of life (QOL) that generic QOL measures do not effectively capture, including activities of daily living that are affected by essential tremor. Baseline, 90 days, and 1 year
Secondary Tremor power Device measured tremor power. Unit: (m/s^2)^2 Continuously measured up to 1 year
Secondary Patient survey Patient survey of satisfaction with the treatment and the durability of the treatment effect 14 days, 30 days, 60 days, 90 days, 180 days, and 1 year
See also
  Status Clinical Trial Phase
Withdrawn NCT05381688 - VIM DBS Respiratory Modulation: N-of-1 Trial
Recruiting NCT05101161 - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes N/A
Completed NCT02277106 - Evaluate SAGE-547 in Participants With Essential Tremor Phase 2
Recruiting NCT05769933 - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Terminated NCT02894567 - Evaluation of Directional Recording and Stimulation Using spiderSTN N/A
Terminated NCT02678429 - Atlas Predicted DBS Settings in Essential Tremor N/A
Completed NCT02523807 - Tremor Monitoring Device N/A
Active, not recruiting NCT02255929 - Gamma Knife Radiosurgery for Treatment of Essential Tremor N/A
Completed NCT01223144 - Decision-making and Emotion Recognition in Essential Tremor N/A
Completed NCT00906412 - Ventrointermediate Nucleus (VIM DBS) and Working Memory N/A
Recruiting NCT05214222 - Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma Phase 2
Completed NCT03051178 - Wearable Sensor for Responsive DBS for ET N/A
Recruiting NCT03795935 - Relief From Side Effects: Clinical Use of Electrodes With Direction N/A
Not yet recruiting NCT06036368 - Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential Tremor N/A
Recruiting NCT05897775 - Coordinated Reset Deep Brain Stimulation for Essential Tremor Phase 1
Recruiting NCT05968976 - Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET N/A
Completed NCT06314139 - Tolerability and Efficacy of Continuous Theta-burst Stimulation for Essential Tremor: A Randomized Study. N/A
Recruiting NCT04501133 - Sensory-specific Peripheral Stimulation for Tremor Management N/A
Active, not recruiting NCT03560622 - Functional Neuroimaging Feedback for Focused Ultrasound Thalamotomy N/A
Completed NCT00368199 - Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes N/A